Thursday, September 30, 2021

Regeneron Covid-19 Trial Meets Primary Endpoint

›
  Regeneron Pharmaceutical Inc. said Thursday that a clinical trial of its REGN-COV candidate treatment for Covid-19 met the drug's prim...

Merck to buy Acceleron for about $11.5 billion in rare disease drugs push

›
  Merck & Co will buy drugmaker Acceleron Pharma Inc for about $11.5 billion, the companies said on Thursday, as the U.S. pharmaceutical...

Bausch: Significant Top Line Results in 2nd Dry Eye Phase 3

›
  Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and Novali...

Trevena: Positive Results in Proof-of-Concept Study in COVID-19

›
  92% probability that TRV027 has a potential beneficial impact on primary endpoint of D-dimer levels, a biomarker associated with critical ...

TG Therapeutics Files with FDA for MS Treatment

›
  TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Ad...
Wednesday, September 29, 2021

37% of COVID patients deal with at least 1 long-term symptom

›
  While many people recover from the initial infection of COVID-19, there has been growing fear of COVID-19 long haulers who have problems m...

Revenue cycle management platform Ensemble Health Partners files for estimated $500M IPO

›
  Ensemble Health Partners, which provides a healthcare revenue cycle management platform, filed on Wednesday with the SEC to raise up to $1...